Development and validation of thin layer chromatography-densitometry method for analysis of mefenamic acid in tablet by Rivai, Harrizul
Available online www.jocpr.com 
 
Journal of Chemical and Pharmaceutical Research, 2016, 8(1):565-570                     
 
 
Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 
 
565 
Development and validation of thin layer chromatography-densitometry 
method for analysis of mefenamic acid in tablet 
 
Harrizul Rivai, Wery Kunia Putri and Fithriani Armin 
 
Faculty of Pharmacy, Andalas University, Padang, West Sumatra, Indonesia 
_____________________________________________________________________________________________ 
 
ABSTRACT 
 
Mefenamic acid is routinely used as tablet dosage forms. Thin layer chromatography (TLC) promotes for higher 
separation efficiencies, shorter analysis time, lower amounts of mobile phase, and efficient data acquisition and 
processing. There are various analytical methods for their estimation of mefenamic acid but till date there is no TLC 
method for its analysis. The paper presents the development and validation of a new TLC method for analysis of 
mefenamic acid in tablet. Separation was performed on silica gel 60 F254 plates. The mobile phase is comprised of 
chloroform: methanol (9.0: 0.1, v: v). Densitometry evaluation of the separated zones was performed at 320 nm. The 
drug was satisfactorily resolved with RF values of 0.55 ± 0.03. The accuracy and reliability of the method was 
assessed by evaluation of linearity (50-300 µg/mL), precision intra-day and inter-day RSD values were always less 
than 2, accuracy (102.45 % ± 1.36% for Sample A and 100.28 % ± 1.90 % for Sample B) in accordance with ICH 
guidelines. The proposed method is new, accurate and precise. Therefore, it is suitable for determination of 
mefenamic acid in tablet for analytical and pharmaceutical purposes. 
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INTRODUCTION 
 
Mefenamic acid is a non-steroidal anti-inflammatory drug used to treat pain, including menstrual pain. It is typically 
prescribed for oral administration. Mefenamic acid has molecular formula C15H15NO2 and molecular weight 241.29 
g/mol. Chemically, mefenamic acid is 2-[(2,3-dimethyl phenyl) amino] benzoic acid as presented in Fig. 1. It is 
metabolized to 3-hydroxymethyl mefenamic acid and further oxidation to a 3-carboxy mefenamic acid may occur. 
The chemical properties for mefenamic acid are white to grayish-white microcrystalline powder, melting point 230 - 
231 oC with effervescence, practically insoluble in water; soluble 1 in 185 mL of ethanol, 1 in 150 ml of chloroform, 
and 1 in 80 mL of ether; soluble in solutions of alkali hydroxides [1]. 
 
 
Fig. 1: Chemical structure of mefenamic acid 
  
The assay of mefenamic acid in tablets is usually carried out by acidi-alkalimetry as Indonesian Pharmacopoeia [2]. 
Literature survey revealed that several methods were used to analysis of mefenamic acid in tablets. These methods 
include electrochemistry, high performance liquid chromatography, ultraviolet-visible spectrophotometry and 
atomic absorption spectrometry [3-6]. 
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The aim of this study is performing very simple method in terms of mobile phase and program to analysis 
mefenamic acid in tablet, and validation of method in according to ICH guideline [7]. 
 
EXPERIMENTAL SECTION 
 
Materials, chemicals and equipment  
Mefenamic acid standards were obtained from PT Indofarma (Jakarta, Indonesia). Tablets of mefenamic acid were 
procured from retail pharmacies (Padang, Indonesia). Methanol, chloroform, glacial acetic acid and ether were 
obtained from E. Merck and of analytical grade. A Camag TLC system equipped with a sample applicator Namomat 
4, twin trough plate development chamber, TLC Scanner III, Reprostar and Wincats 4.02, integration software 
(Switzerland). Pre-coated silica gel 60 F254 TLC aluminum plates were obtained from E. Merck, Jakarta (Indonesia).  
 
Preparation of standard solution 
Weigh accurately 25.3 mg mefenamic acid and was dissolved in 20 mL chloroform in 50 mL volumetric flask. This 
solution was sonicated for 15 minutes at 30 oC and then added chloroform up to mark to get the strength of 506 
µg/mL mefenamic acid.  
 
Method Development 
Mefenamic acid solution was prepared using chloroform as solvent. The TLC plates were pre washed with methanol 
and activated by keeping at 115°C for about 30 minutes. Solutions of 2.0 µL were applied on the TLC plates as 
using Camag Nanomat 4. Application positions were at least 10 mm from the sides and 10 mm from the bottom of 
the plates. Mobile phase components were mixed prior to use and the development chamber was left to saturate with 
mobile phase vapor for 15 minutes before each run. Mobile phase components were listed in Table 1. 
 
Table 1: Component of mobile phase used in TLC of mefenamic acid analysis 
 
Component of mobile phase Ratio Rf 
Methanol : Chloroform : Acetic acid 8 : 10 : 0.2 0.87 
Methanol : Chloroform : Acetic acid 3 : 7 : 2 drops 0.85 
Dichloromethane : Methanol : Acetic acid 4 : 1 : 2 drops 0,86 
Dichloromethane : Methanol 2 : 3 0,78 
Dichloromethane : Methanol 4 : 1 0,78 
Dichloromethane 1 0,88 
Chloroform 1 0,30 
Chloroform : Methanol 9.9 : 0.1 0.55 
 
Development of the plates was carried out by the ascending technique to a migration distance of 8 cm. The plates 
were dried by hair dryer. 
 
Densitometry scanning was done in absorbance mode at 320 nm using a deuterium lamp. The slit dimensions were 
set at 6 x 0.30 mm, the scanning speed at 20 mm/s and data resolution at 100 m/step. Single wavelength detection 
was performed because we are dealing with main component analysis and not impurities determinations where 
scanning at the individual λ values would be preferred. 
 
These conditions were transferred to the TLC system and the results were evaluated with the aim of achieving an 
optimum separation between spots (Rs ≥ 2) and a migration of spots with Rf values between 0.32 and 0.55 in order 
to ensure separation reproducibility. 
 
Method Validation 
Linearity 
A stock solution with 506 µg/mL of mefenamic acid was prepared in chloroform. The volume of 1, 2, 3, 4 and 5 mL 
of stock solution were introduced by measuring pipette into separate 10 mL volumetric flask and then diluted with 
chloroform up to the mark. These solutions contain 50.6, 101.2, 151.8, 202.4, 253.0 µg/mL of mefenamic acid. A 
volume of 5 µL of each solution was applied on the TLC plate. This was done in triplicate and repeated for three 
days. For each concentration, the applied spot were evenly distributed across the plate to minimize possible variation 
along the silica layer. The linearity was evaluated visually by looking at the calibration curve of mefenamic acid. 
 
Precision 
The repeatability and time-different intermediate precision were determined simultaneously. Intra-day assay 
precision was found by analysis of standard drug at three times on the same day. Inter-day assay precision was 
carried out using at three different days and percentage relative standard deviation (% RSD) was calculated. The 
RSD was found to be less than two for both intra-day and inter-day precision. Repeatability of sample application 
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was assessed by spotting 101.2, 202.4 and 253.0 µg/mL of mefenamic acid solution, and three times. From the peak 
areas, the percentage RSD was determined.  
 
Accuracy 
The accuracy of the method was assessed by determination of the recovery of the method at three different 
concentrations (40%, 80% and 120% concentration) by addition of known amount of standard to the placebo. 
Solutions were prepared in triplicate and analyzed. This procedure was repeated for three consecutive days. 
Calibration curves to estimate the concentration of drug per spot were measured daily on the same plates as the 
samples. The accuracy was determined and expressed as percentage recovery. 
 
Analysis of tablet samples 
The method was used for quantization of mefenamic acid procured from local pharmacy. For sample preparation, 
chloroform was used as solvent for extraction and dilution. Twenty tablets containing mefenamic acid were milled 
well and weighed accurately. Portions of powder equivalent to 10 mg of mefenamic acid was weighed accurately 
and introduced into a 50 mL volumetric flask. The mixture was diluted up to 50 mL volume with chloroform; mixed 
well and filtered through Whatmann filter paper No 41 to obtain the sample stock solution. Further 5 µL of the test 
solution was applied on the pre-coated silica gel 60 F254 plate and from the peak area obtained; the amount of 
mefenamic acid in tablet was calculated using the calibration graph.  
 
For the determination of mefenamic acid, sample solutions were prepared in triplicate and analyzed according to the 
method procedure. Sample and standard solutions were spotted on the same plate. 
 
Reproducibility 
Reproducibility is assessed by means of an inter-laboratory trial. Reproducibility should be considered in case of the 
standardization of an analytical procedure, for instance, for inclusion of procedures in Pharmacopoeias. These data 
are not part of the marketing authorization dossier. 
 
Repeatability 
Repeatability should be assessed using a minimum of 9 determinations covering the specified range for the 
procedure (e.g., 3 concentrations /3 replicates each). 
 
RESULTS AND DISCUSSION 
 
During the stage of method development different mobile phases were tried and the mobile phase comprising of 
chloroform and methanol (9.9: 0.1, v: v) was confirmed. Component of mobile phases used in TLC of mefenamic 
acid analysis were listed in Table 1. This table showed that Rf value 0.55 was the best mobile phase for TLC of 
mefenamic acid analysis by using silica gel 60 F254 plate. 
 
A good linear relationship was obtained over the concentration range 50-300 µg/mL with linear regression Y = 
12.558 X + 414.1 and coefficient correlation of 0.997 (Fig. 2). The LOD was found to be 27.10 µg/mL. The LOQ 
was found to be 82.13 µg/mL. The repeatability showed excellent % RSD less than 2 % after six applications (Table 
2 and Table 3). 
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Fig. 2: Calibration curve of mefenamic acid 
 
Table 2: Evaluation of interday precision of mefenamic acid 
 
Concentration added (µg/mL) Day Area Under Curve Concentration obtained (µg/mL) SD RSD 
101.2 
1 
1681 100.9 
1.59 1.43 
1675 100.4 
1690 101.6 
2 
1710 103.2 
1670 100.0 
1701 102.5 
3 
1676 100.5 
1640 97.6 
1681 100.9 
202.4 
1 
2960 202.7 
1.85 0.88 
2955 202.3 
2945 201.5 
2 
2971 203.6 
2962 202.9 
2904 198.3 
3 
2910 198.7 
2934 200.7 
2951 202.0 
303.6 
1 
4250 305.5 
1.06 0.35 
4221 303.1 
4232 304.0 
2 
4244 305.0 
4240 304.7 
4235 304.3 
3 
4210 302.3 
4216 302.7 
4236 304.3 
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Table 3: Evaluation of intraday precision of mefenamic acid 
 
Concentration added (µg/mL) Time on a day Area Under Curve Concentration obtained (µg/mL) SD RSD 
101.2 
1 
1669 99.9 
1.43 1.30 
1676 100.5 
1688 101.4 
2 
1703 102.6 
1675 100.4 
1640 97.6 
3 
1677 100.6 
1655 98.8 
1675 100.4 
202.4 
1 
2958 202.6 
0.70 0.33 
2947 201.7 
2940 201.1 
2 
2970 203.5 
2950 201.9 
2948 201.8 
3 
2960 202.7 
2952 202.1 
2949 201.9 
303.6 
1 
4244 305.0 
1.15   0.38  
4251 305.5 
4250 305.5 
2 
4220 303.1 
4235 304.3 
4226 303.5 
3 
4215 302.7 
4220 303.1 
4217 302.8 
 
Recovery studies were carried out for estimation of the accuracy of the proposed method. These studies were carried 
out using standard addition method at three concentration levels. The obtained results were summarized in Table 4. 
The low RSD value (< 2) indicated the suitability of the method for routine analysis of mefenamic acid in 
pharmaceutical tablets. 
 
Table 4: Standard addition method for the recovery studies 
 
% 
Added 
Concentration of 
standard added 
(µg/mL) 
Area 
Under 
Curve 
Concentration after 
standard addition 
(µg/mL) 
Concentration before 
standard addition 
(µg/mL) 
% 
Recovery Average SD RSD 
40 79.2398 
3961.4 282.5 
198.0995 
106.48 
105.93 0.51 0.48 3955.2 282.0 105.86 
3951.3 281.7 105.46 
80 158.4796 
4905.6 357.7 
198.0995 
100.68 
101.15 1.38 1.36 4945.7 360.9 102.70 
4893.2 356.7 100.06 
120 237.7194 
6095.4 452.4 
198.0995 
106.98 
105.48 1.31 1.24 6034.2 447.5 104.93 
6022.5 446.6 104.54 
 
The proposed chromatographic method was finally applied for the determination of mefenamic acid in the 
commercially available dosage forms. The obtained results of the present method were showed on Table 5. This 
confirms that the assay value lies within the limit specified in the Indonesian Pharmacopoeia [2]. 
 
CONCLUSION 
 
In this work, TLC technique was developed and validated for the analysis of mefenamic acid in pharmaceutical 
tablets. The proposed method is simple, accurate and highly selective for mefenamic acid. The satisfactory 
sensitivity and simplicity make the methods suitable for routine analysis of mefenamic acid in quality control 
laboratories. 
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Table 5: Analysis of commercial tablets containing mefenamic acid 
 
Sample Labeled Content (mg/tablet) 
Area Under 
Curve 
Concentration obtained 
(µg/mL) 
% Mefenamic 
Acid Average SD RSD 
A 500 
2,975.3 203.9 101.85 
102.45 1.36 1.33 
2,996.1 205.6 102.68 
3,057.8 210.5 105.14 
2,997.4 205.7 102.73 
2,990.0 205.1 102.44 
2,984.9 204.7 102.24 
2,988.8 205.0 102.39 
2,924.1 199.9 99.82 
2,998.1 205.8 102.76 
B 500 
2,971.7 203.7 101.71 
100.28 1.90 1.90 
2,948.5 201.8 100.79 
2,968.0 203.4 101.56 
2,940.1 201.1 100.45 
2,979.1 204.3 102.01 
2,952.3 202.1 100.94 
2,935.8 200.8 100.28 
2,824.6 191.9 95.86 
2,900.4 198.0 98.88 
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